Arecoline Fundamentals Explained
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze to evaluate multiple intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Principal demo targets were To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis